(VIANEWS) – VISTIN PHARMA (VISTN.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| VISTIN PHARMA (VISTN.OL) | kr22.40 | 7.71% | 19.84% |
| CONTEXTVISION (CONTX.OL) | kr6.10 | 3.46% | 61.1% |
| EUROFINS SCIENT. (ERF.PA) | €59.08 | 1.07% | 6.16% |
| TUBIZE-FIN (TUB.BR) | €107.00 | 0.93% | 4.97% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. VISTIN PHARMA (VISTN.OL)
7.71% Forward Dividend Yield and 19.84% Return On Equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.27.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.64. Meaning, the purchaser of the share is investing kr17.64 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.84%.
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr22.40 at 07:30 EST, way under its 52-week high of kr25.00 and higher than its 52-week low of kr20.60.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.9%, now sitting on 441.27M for the twelve trailing months.
More news about VISTIN PHARMA.
2. CONTEXTVISION (CONTX.OL)
3.46% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and America. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary uses. Its products include Rivent that offers image enhancement and visualization solutions for ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, a 2D image enhancement product for handheld units; and Rivent 3D, an image enhancement solution for 3D ultrasound. The company also provides Altumira/Altumira Plus, an artificial intelligence-powered image enhancement product for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. ContextVision AB (publ) was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.42.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 14.52. Meaning, the purchaser of the share is investing kr14.52 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
Yearly Top and Bottom Value
CONTEXTVISION’s stock is valued at kr6.10 at 07:30 EST, way under its 52-week low of kr7.80.
Moving Average
CONTEXTVISION’s value is way below its 50-day moving average of kr8.37 and way under its 200-day moving average of kr8.72.
Volatility
CONTEXTVISION’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.17%, a positive 0.12%, and a positive 1.70%.
CONTEXTVISION’s highest amplitude of average volatility was 2.17% (last week), 1.73% (last month), and 1.70% (last quarter).
Volume
Today’s last reported volume for CONTEXTVISION is 7446 which is 88.67% below its average volume of 65755.
More news about CONTEXTVISION.
3. EUROFINS SCIENT. (ERF.PA)
1.07% Forward Dividend Yield and 6.16% Return On Equity
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €1.57.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 37.63. Meaning, the purchaser of the share is investing €37.63 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.1%, now sitting on 6.51B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUROFINS SCIENT.’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for EUROFINS SCIENT. is 432940 which is 35.04% above its average volume of 320589.
More news about EUROFINS SCIENT..
4. TUBIZE-FIN (TUB.BR)
0.93% Forward Dividend Yield and 4.97% Return On Equity
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.98.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 54.04. Meaning, the purchaser of the share is investing €54.04 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.97%.
Moving Average
TUBIZE-FIN’s worth is higher than its 50-day moving average of €99.30 and way above its 200-day moving average of €81.09.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €107.00 at 07:30 EST, under its 52-week high of €109.20 and way higher than its 52-week low of €60.80.
Volatility
TUBIZE-FIN’s last week, last month’s, and last quarter’s current intraday variation average was 0.71%, 0.36%, and 1.02%.
TUBIZE-FIN’s highest amplitude of average volatility was 1.34% (last week), 1.16% (last month), and 1.02% (last quarter).
More news about TUBIZE-FIN.
